Predict your next investment

Venture Capital
clave.capital

See what CB Insights has to offer

Investments

61

Portfolio Exits

2

Funds

14

About Clave

Clave supports innovative projects and industrial SMEs, through investments or immersion in the process of creating value for the company.

Clave Headquarter Location

C/Emilio Arrieta, 11 bis - 2º

Pamplona, 31002,

Spain

+34 948 203 960

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Clave

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Clave in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Clave News

Corify Care Closes a €2.3 Million Round Led by Clave Capital

Jul 9, 2021

Corify Care has recently closed a financing round during which it raised $2.7 million (€2.3 million). The Spanish company, which is developing a non-invasive cardiac mapping system, has also received financial backing from the Mondragon Corporation, Bexen Cardio and the Cdti. This investment complements the money raised through the crowdfunding platform Capital Cell. 0 Corify Care has recently attracted capital . The Spanish company, which develops a non-invasive cardiac mapping system, has closed a $2.7 million (€2.3 million) financing round. The deal was led by Clave Capital. The round has also counted with the participation of the Mondragon Corporation, Bexen Cardio, and the Center for Industrial Technological Development (Cdti), through its Innvierte program, which co-invest $1.4 million (€1.2 million) along with 465 individual investors who contribute up to $1.3 million (€1.1 million) through crowdfunding rounds organized together with Capital Cell. This investment is channeled through the Mondragon fund, controlled by the Mondragon Corporation. The corporation constitutes a group of cooperatives and companies, as is the case of Bexen Cardio, a medical company in the cardiology sector and part of the Mondragon Group cooperative that has also invested in Corify Care. Read more about Corify Care and find the most important business news with the Born2Invets mobile app. Corify Care has managed to raise $1.3 million (€1.1 million) through Capital Cell This investment complements the money raised through the crowdfunding platform Capital Cell through which Corify Care has been able to raise $1.3 million (€1.1 million) in two campaigns with the participation of more than 400 investors, including professionals in the field of cardiology, various family offices, and other investors with experience in the health sector. Founded in 2019, Corify Care has created Acorys, its first device, which is poised to transform the process of treating cardiac arrhythmias. Acorys is based on technology developed in collaboration between the Hospital General Universitario Gregorio Marañón and the Itaca Institute of the Polytechnic University of Valencia. This first Corify Care device will enable personalized treatment of cardiac arrhythmias. To date, the company has brought the product to the final design version and validated the technology with more than 300 patients. In 2020, Acorys received the European Institute of Innovation and Technology award for best innovation endowed with $59,000 (€50,000). In addition, Corify Care has initiated pre-commercial activity of this device through agreements and projects in the framework of research with medical centers nationwide such as the Hospital Clínic de Barcelona. The round will enable Acorys to complete clinical validation, obtain regulatory approval in Europe and the United States in 2023, and launch the device on the domestic and international markets. The company expects to obtain regulatory approval in Europe and the United States in 2023 Andreu Climent, CEO of the company, explained that “we are excited to be able to complete our ambitious development plan and finalize clinical validation and go to market” and adds that “we are confident that our device will be able to help physicians optimize both effectiveness and efficiency when performing complex procedures to treat cardiac rhythm disturbances”. Worldwide, 33.5 million people suffer from cardiac arrhythmia, a figure that will more than double by 2050. In the European Union, 500,000 people die each year due to arrhythmia. With the aging of the population, it is estimated that cardiac arrhythmia will affect more than 50 million people by 2050. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  PlantaDoce , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Clave Investments

61 Investments

Clave has made 61 investments. Their latest investment was in Multiverse Computing as part of their Seed VC - II on October 10, 2021.

CBI Logo

Clave Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/20/2021

Seed VC - II

Multiverse Computing

$11.55M

Yes

6

7/28/2021

Seed VC

Nexkin Medical

$0.95M

Yes

1

7/27/2021

Seed VC

MainRail

$1.3M

Yes

1

7/9/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/15/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/20/2021

7/28/2021

7/27/2021

7/9/2021

6/15/2021

Round

Seed VC - II

Seed VC

Seed VC

Seed VC

Seed VC

Company

Multiverse Computing

Nexkin Medical

MainRail

Subscribe to see more

Subscribe to see more

Amount

$11.55M

$0.95M

$1.3M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

1

10

10

Clave Portfolio Exits

2 Portfolio Exits

Clave has 2 portfolio exits. Their latest portfolio exit was Cytognos on July 25, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/25/2018

Leveraged Buyout

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/25/2018

00/00/0000

Exit

Leveraged Buyout

Subscribe to see more

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

1

10

Clave Acquisitions

5 Acquisitions

Clave acquired 5 companies. Their latest acquisition was Coalza Systems on July 19, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/19/2019

Acq - Fin

1

3/13/2017

Subscribe to see more

$99M

Subscribe to see more

10

7/30/2011

Subscribe to see more

$99M

Subscribe to see more

10

2/28/2011

Leveraged Buyout

Subscribe to see more

$99M

Subscribe to see more

10

5/30/2007

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/19/2019

3/13/2017

7/30/2011

2/28/2011

5/30/2007

Investment Stage

Leveraged Buyout

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$99M

$99M

$99M

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Clave Fund History

14 Fund Histories

Clave has 14 funds, including UN I+D+i Technology Transfer.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/12/2017

UN I+D+i Technology Transfer

Early-Stage Venture Capital

$4.76M

1

11/27/2017

Mondragon Fondo de Promocion FCR

Early-Stage Venture Capital

$17.49M

1

1/28/2016

Tech Transfer UPV FCR

Multi-Stage Venture Capital

$6.45M

1

12/31/2006

Ronda Tic

Subscribe to see more

$99M

10

12/31/2006

Valencia Emprende

Subscribe to see more

$99M

10

Closing Date

12/12/2017

11/27/2017

1/28/2016

12/31/2006

12/31/2006

Fund

UN I+D+i Technology Transfer

Mondragon Fondo de Promocion FCR

Tech Transfer UPV FCR

Ronda Tic

Valencia Emprende

Fund Type

Early-Stage Venture Capital

Early-Stage Venture Capital

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$4.76M

$17.49M

$6.45M

$99M

$99M

Sources

1

1

1

10

10

Clave Team

1 Team Member

Clave has 1 team member, including current Chief Executive Officer, President, Jose Javier Armendariz Quel.

Name

Work History

Title

Status

Jose Javier Armendariz Quel

Chief Executive Officer, President

Current

Name

Jose Javier Armendariz Quel

Work History

Title

Chief Executive Officer, President

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.